Top Qs
Timeline
Chat
Perspective

Bimagrumab

Chemical compound From Wikipedia, the free encyclopedia

Remove ads

Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis[citation needed] to treat pathological muscle loss and weakness. It binds to and inhibits activin receptor type-2B.[1]

Quick Facts Monoclonal antibody, Type ...

Bimagrumab must be administered intravenously at a hospital or clinic. The medication has a long half-life and is administered once a month.[2]

Remove ads

Development history

On August 20, 2013, it was announced that bimagrumab had received a breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by the US Food and Drug Administration (FDA).[3]

In 2014, Bimagrumab entered Phase II development, with some research indicating clinical effects.[4] Novartis planned to apply in 2016 for FDA approval to treat sIBM patients with bimagrumab.[5]

In April 2016, Novartis announced that bimagrumab had failed a Phase IIb/III study for sporadic inclusion body myositis.[6] In January 2021, a new study confirmed that treatment with bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes.[7] In January 2023 the medication entered phase IIb trials for obesity.[2]

Remove ads

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads